Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
Abstract Kynurenine 3-monooxygenase (KMO) regulates the levels of neuroactive metabolites in the kynurenine pathway (KP), dysregulation of which is associated with Huntington’s disease (HD) pathogenesis. KMO inhibition leads to increased levels of neuroprotective relative to neurotoxic metabolites,...
Guardado en:
Autores principales: | Marie Katrin Bondulich, Yilan Fan, Yeojin Song, Flaviano Giorgini, Gillian P. Bates |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3d08dbe362e24d8e84f312c876b96a6c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition
por: Shinya Mimasu, et al.
Publicado: (2021) -
Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase
por: Jonathan P. Hutchinson, et al.
Publicado: (2017) -
Human glia can both induce and rescue aspects of disease phenotype in Huntington disease
por: Abdellatif Benraiss, et al.
Publicado: (2016) -
Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
por: Lara Moumné, et al.
Publicado: (2012) -
Publisher Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington’s disease
por: Rebecca Aron, et al.
Publicado: (2018)